Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

252P - Risk factors for recurrence after curative nephrectomy in non-metastatic renal cell carcinoma: A retrospective cohort study

Date

02 Dec 2023

Session

Poster Display

Presenters

Kristine Tejada

Citation

Annals of Oncology (2023) 34 (suppl_4): S1556-S1571. 10.1016/annonc/annonc1381

Authors

K.G. Tejada

Author affiliations

  • Medical Oncology Department, National Kidney and Transplant Institute, 1101 - Quezon City/PH

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 252P

Background

RCC accounts for nearly 4% of all malignancies, in the Philippines, RCC ranks as the 15th most common cancer in 2018. The National Kidney and Transplant institute Cancer registry ranks RCC as the institute’s 4th most common malignancy at 10%. Studies to improve the diagnostic work up and follow up of this rare malignancy but apparently common in this institution can contribute for a better management and characterization of RCC.

Methods

This is a retrospective cohort study which included all patients who underwent nephrectomy for localized renal cell cancer from January 2017 to December 2021.

Results

There were 464 eligible patients included in this study. Clinical factors associated with recurrence of RCC upon multivariate analysis are bilateral sidedness, pT2 and beyond, WHO Grade 3-4, tumor encompassing the entire kidney, sarcomatoid and rhabdoid features, tumor necrosis, tumor thrombus, lymphovascular space invasion and positive surgical margins. Most common sites of recurrence was lungs (58.33%) followed by lymph nodes (45.83%) then bones (20.83%).

Conclusions

Presence of poor prognostic factors as well as positive lymph nodes are highly associated with local and distant RCC recurrence. A more stringent follow up with appropriate imaging may allow early intervention of metastatic diseases and possible consideration of lymph node dissection may improve recurrence free survival.

Clinical trial identification

Editorial acknowledgement

101 Health research.

Legal entity responsible for the study

The author.

Funding

National Kidney and Transplant Institute.

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.